[Blood prolactin-lowering activity of dihydroergocristine].

The prolactin lowering activity of dihydroergocristine, a dihydrogenated ergopeptine derivative, was evaluated in male rats. The drug caused a significant decrease of prolactin levels both in the normoprolactinemic animals and in reserpine-induced hyperprolactinaemia at 5 mg/kg p.o. while 0.2 and 1 mg/kg p.o. were ineffective. In a second experiment the prolactin lowering activity of dihydroergocristine (0.2; 1.5 mg/kg), in reserpine-induced hyperprolactinaemia was compared with bromocryptine (0.1; 0.5; 2.5 mg/kg) administered intraperitoneally. Both dihydroergocristine and bromocryptine caused a significant decrease of prolactin plasma concentrations at all dose levels. Moreover the prolactin lowering effect was independent of the dose administered. Our data suggest prolactin lowering activity of oral or i.p. dihydroergocristine both on normal plasma concentrations and on the experimentally-induced hypersecretion of the hormone.